GLP-1 and metformin

How metformin and GLP-1 complement each other

Metformin and GLP-1 are both first-line medicines for type 2 diabetes, but they work via completely different mechanisms. That explains why they complement each other so well — and why doctors often prescribe them together.

Metformin inhibits glucose production in the liver (gluconeogenesis), improves the insulin sensitivity of muscles and liver, and has a slight effect on appetite. It acts on fasting blood sugar and has a half-life of a few hours, hence it is usually taken twice daily.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) stimulate insulin release at meals, inhibit glucagon secretion, slow gastric emptying and suppress appetite via the hypothalamus. They act mainly on postprandial blood sugar (after meals) and have a longer half-life (1 week for semaglutide, daily for liraglutide).

The complementary mechanism means that the effect on HbA1c (the long-term blood sugar marker) is greater with the combination than with either alone. Studies show an average HbA1c reduction of 1.5-2.0% with the combination versus 0.8-1.2% with monotherapy.

When the combination is useful

The combination metformin + GLP-1 is used clinically for three main indications: advanced type 2 diabetes (HbA1c >7% despite metformin alone), prediabetes with obesity, and PCOS with insulin resistance and/or excess weight.

For patients without diabetes or prediabetes — a pure obesity indication — metformin is rarely needed alongside GLP-1. Adding it gives limited extra weight loss but does add side effects. In that situation we usually opt for GLP-1 monotherapy.

The Dutch NHG guideline 'Diabetes Mellitus Type 2' (2024) advises continuing metformin as the first step when adding a GLP-1 — unless metformin is not tolerated or is contraindicated.

The combination in type 2 diabetes

In type 2 diabetes, metformin is the cornerstone of treatment: first step, lifelong, at a dose of usually 1500-2000 mg per day. If HbA1c remains above 7% despite maximum metformin and lifestyle advice, a GLP-1 (Ozempic 1 mg or Mounjaro 7.5-15 mg) is nowadays the preferred second step. In 2023 this replaced the previously used sulfonylureas as the second choice.

Benefits of the combination: greater HbA1c reduction, weight loss (5-15% depending on the GLP-1 chosen), lower risk of cardiovascular complications, lower risk of chronic kidney damage. The SUSTAIN and SURPASS trials all showed that semaglutide and tirzepatide are the most effective for both glucose and weight control.

Reimbursement: in type 2 diabetes with a demonstrated indication, both metformin and most GLP-1 medicines are reimbursed from basic health insurance. Since 2024, Mounjaro has also been on the GVS formulary in the Netherlands for diabetes.

The combination in obesity and prediabetes

In prediabetes (HbA1c 5.7-6.4%) with obesity, GLP-1 can be used to prevent progression to type 2 diabetes. Metformin can be added in this setting, but the evidence is more limited than in full diabetes.

The landmark Diabetes Prevention Program (DPP) showed that metformin 1500 mg/day lowers the risk of progression to type 2 diabetes by ~30% in prediabetes — comparable to intensive lifestyle intervention. In comparable studies, GLP-1 is more effective in both prevention and weight loss.

Our preference in prediabetes with BMI >30: start with GLP-1 (Wegovy or Mounjaro) and add metformin if fasting glucose continues to rise. This is more conservative than starting both at the same time and makes it easier to attribute side effects.

The combination in PCOS

Polycystic ovary syndrome (PCOS) is often accompanied by insulin resistance and excess weight. Metformin has been used for decades in PCOS to improve insulin resistance and restore ovulation — not under the official label but as established off-label practice.

Adding GLP-1 in women with PCOS and excess weight gives stronger weight loss and better restoration of menstrual regularity than metformin alone. At Go Leaner, the combination is a frequently used approach in women with PCOS, provided there is no active wish to conceive (see our article on GLP-1 and pregnancy).

Important: GLP-1 is stopped at least 2 months before conception; metformin can often be continued during pregnancy in PCOS. Make a personal tapering plan with your doctor if you wish to conceive.

Side effects — what changes

Both medicines cause gastrointestinal side effects — mainly nausea, diarrhoea and abdominal pain. With the combination these are not simply the sum of both, but they can reinforce each other in the first 4-8 weeks.

Practical tips to limit side effects: start metformin 2-4 weeks before GLP-1 so that you have got through the metformin side effects before you begin GLP-1. Build both up gradually (not the maximum dose straight away). Take metformin with meals — never on an empty stomach. Use metformin MR (slow release) for persistent diarrhoea.

Other side effects of the combination: a slight drop in vitamin B12 with long-term metformin (a check every 2 years is advised), possibly a slight rise in lactate (rarely clinically relevant), and interaction with alcohol can worsen diarrhoea (see our article on Ozempic and alcohol).

Dosing and titration schedule for the combination

Metformin is built up from 500 mg per day to 1500-2000 mg in steps of 500 mg per week or per 2 weeks — depending on tolerability. The maximum dose is 3000 mg/day, but above 2000 mg the efficacy does not increase much further while side effects do.

GLP-1 is built up via the standard titration schedule of the medicine itself (Ozempic 0.25 → 0.5 → 1.0 mg, Mounjaro 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, Wegovy similar). With the combination, the GLP-1 titration does not need to be adjusted compared with monotherapy.

Optimal order: first get metformin stable at an effective dose, then add GLP-1 and titrate step by step. This gives the best tolerability and the clearest measurement of effect.

Risk of hypoglycaemia

Good news: neither metformin nor GLP-1 causes hypoglycaemia (low blood sugar) as monotherapy. Both medicines only act when insulin action is needed — at normal or low blood sugar they dampen their own effect.

However: in combination with sulfonylureas (glimepiride, gliclazide) or insulin, the risk of hypoglycaemia can increase. Practical advice: when starting GLP-1, the sulfonylurea dose is often halved and the insulin dose lowered by 20-30% to prevent hypos.

A patient using only metformin + GLP-1 without other blood-sugar medication therefore has no increased risk of hypos. We do advise patients with diabetes to own a glucose meter and to recognise the symptoms of a hypo.

When to advise against the combination

The combination is advised against in a few situations: severe kidney impairment (eGFR <30 ml/min), in which case metformin is contraindicated. Active diarrhoea or dehydration, as both medicines make this worse. Severe liver disease with cirrhosis. An active eating disorder, because the combination suppresses appetite even more strongly.

In pregnancy or breastfeeding: GLP-1 is stopped; metformin may be continued for some indications (gestational diabetes, PCOS) under obstetric supervision.

At Go Leaner we assess at every intake whether the combination is useful. In pure obesity (without diabetes or PCOS) we often advise starting with GLP-1 monotherapy and adding metformin only if laboratory values indicate it.